SCHEMBL7479786

SCHEMBL7479786

Cc1nccn1CN1CCOCC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.43
JAK2 O60674 1/20 0.39
CHRM2 P08172 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
P2RX7 Q99572 1/20 0.38
KCNH2 Q12809 1/20 0.38
TSHR P16473 1/20 0.37
FDPS P14324 1/20 0.37
CYP2A13 Q16696 1/20 0.37
LMNA P02545 2/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 1/20 0.36
PIK3CA P42336 1/20 0.36
MTOR P42345 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14553277 0.86 ALDH1A1 (0.51) ALDH1A1KMT2APOLBCHRM2CHRM1
SCHEMBL8149708 0.82 ALDH1A1 (0.46) ALDH1A1KMT2APOLBCHRM2CHRM5
SCHEMBL14083460 0.77 ALDH1A1 (0.41) ALDH1A1KMT2APOLBCHRM2CHRM5
SCHEMBL4772963 0.77 KMT2A (0.59) ALDH1A1KMT2APOLBCHRM2CHRM5
SCHEMBL10726249 0.74 SMN1; SMN2 (0.49) ALDH1A1KMT2APOLBTSHRLMNA
SCHEMBL4319831 0.73 KDM4E (0.41) ALDH1A1POLBTSHRLMNAHPGD
SCHEMBL11210727 0.71 KMT2A (0.55) ALDH1A1KMT2APOLBCHRM2CHRM5
SCHEMBL15619179 0.71 KMT2A (0.53) ALDH1A1KMT2APOLBCHRM2CHRM5
SCHEMBL23204979 0.71 BRD4 (0.54) ALDH1A1KMT2APOLBKCNH2TSHR
SCHEMBL8697896 0.70 KMT2A (0.53) ALDH1A1KMT2APOLBCHRM2CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020061919-A1 PROCESS FOR THE PREPARATION OF 1,2,3,9-TETRAHYDRO-9-METHYL-3-{(2-METHYL-1H-IMIDAZOL-1-YL)METHYL}-4H-CARBAZOL-4-ONE HANMI PHARM. CO., LTD. (KR) 2002-05-23 US disclosed
EP-1207160-A1 Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)-methyl)-4H-carbazol-4-one Hanmi Pharm. Co., Ltd. (KR) 2002-05-22 EP disclosed
US-6388091-B1 IN PRESENCE OF A HALOSILANE COMPOUND; CRYSTALLIZATION, PURIFICATION HANMI PHARM. CO., LTD. (KR) 2002-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061919-A1 PROCESS FOR THE PREPARATION OF 1,2,3,9-TETRAHYDRO-9-METHYL-3-{(2-METHYL-1H-IMIDAZOL-1-YL)METHYL}-4H-CARBAZOL-4-ONE JAK1, CILK1, AZI2 ALDH1A1 1316/4885KMT2A 217/4885POLB 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.